Nektar Therapeutics

NKTR
Delayed Nasdaq - 05/17 10:00:00 pm
32.02USD
+2.17%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20182019
Sales1 193111
EBITDA699-514
Operating profit (EBIT)688-539
Pre-Tax Profit (EBT)--
Net income681-538
EPS ( $ )3,78-3,08
Dividend per Share ( $ )--
Yield--
Announcement Date02/28/2019
09:10pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20182019
Debt--
Finance1 0881 409
Operating income (EBITDA)699-514
Leverage
(Debt/EBITDA)
--
Capital Expenditure14,211,2
Book Value Per Share (BVPS)9,90 $7,43 $
Cash Flow per Share4,64 $-2,39 $
Announcement Date02/28/2019
09:10pm
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 5 581 M$ -
Entreprise Value (EV) 4 172 M$ 5 015 M$
Valuation 2019e 2020e
P/E ratio (Price / EPS)
Capitalization / Revenue 50,2x 27,3x
EV / Revenue 37,5x 24,5x
EV / EBITDA -8,12x -9,85x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 4,31x 6,12x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -485% -237%
operating Leverage (Delta EBIT / Delta Sales) -1,97x 0,12x
Net Margin (Net Profit / Revenue) -484% -213%
ROA (Net Profit / Asset) -28,4% -18,8%
ROE (Net Profit / Equities) -37,9% -32,1%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   10,1% 5,84%
Cash Flow / Sales -375% -223%
Capital Intensity (Assets / Sales) 17,1x 11,3x
Financial Leverage (Net Debt / EBITDA) 2,74x 1,11x
Price Earning Ratio
BNA & Dividende